Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
Elisabetta Perrone, Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra, Luca Zammataro, Aranzazu Manzano, Paola Manara, Anna Bianchi, Natalia Buza, Joan Tymon-Rosario, Gary Altwerger, Chanhee Han, Gulden Menderes, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Pei Hui, Peter E. SchwartzGiovanni Scambia, Alessandro D. Santin
Dive into the research topics of 'Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer'. Together they form a unique fingerprint.